State Street
TCRX icon

State Street’s TScan Therapeutics TCRX Stock Holding History

State Street’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$203K Hold
207,313
– – ﹤0.01% 3827
2026
Q1 		$209K Hold
207,313
– – ﹤0.01% 3872
2025
Q4 		$207K Buy
207,313
+10,000
+5% +$14.5K ﹤0.01% 3893
2025
Q3 		$359K Sell
197,313
-3,200
-2% -$5.67K ﹤0.01% 3734
2025
Q2 		$291K Sell
200,513
-616,735
-75% -$891K ﹤0.01% 3737
2025
Q1 		$1.13M Buy
817,248
+16,300
+2% +$35.3K ﹤0.01% 3401
2024
Q4 		$2.43M Buy
800,948
+44,449
+6% +$201K ﹤0.01% 3252
2024
Q3 		$3.77M Buy
756,499
+148,414
+24% +$895K ﹤0.01% 3090
2024
Q2 		$3.56M Buy
608,085
+473,085
+350% +$3.73M ﹤0.01% 3077
2024
Q1 		$1.07M Buy
135,000
+73,900
+121% +$465K ﹤0.01% 3453
2023
Q4 		$356K Buy
61,100
+19,400
+47% +$88.8K ﹤0.01% 3726
2023
Q3 		$107K Buy
41,700
+3,200
+8% +$7.47K ﹤0.01% 4105
2023
Q2 		$96.3K Buy
38,500
+14,500
+60% +$38.9K ﹤0.01% 4254
2023
Q1 		$50.4K Buy
24,000
+10,600
+79% +$25.2K ﹤0.01% 4500
2022
Q4 		$21.8K Hold
13,400
– – ﹤0.01% 4718
2022
Q3 		$41K Hold
13,400
– – ﹤0.01% 4698
2022
Q2 		$42K Buy
13,400
+800
+6% +$2.19K ﹤0.01% 4754
2022
Q1 		$35K Buy
12,600
+400
+3% +$1.73K ﹤0.01% 4849
2021
Q4 		$55K Hold
12,200
– – ﹤0.01% 4688
2021
Q3 		$102K Buy
+12,200
New +$113K ﹤0.01% 4541

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

State Street's TCRX Position: Q2 2026 in Review

State Street held its TScan Therapeutics (TCRX) position steady in Q2 2026 at 207,313 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #3827.

State Street first reported a position in TCRX in Q3 2021 and has held it in 20 quarters since. The position peaked at $3.77M in Q3 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • State Street held 207,313 shares of TScan Therapeutics worth $203K as of Q2 2026.
  • State Street left its TScan Therapeutics share count unchanged in Q2 2026.
  • TScan Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3827 holding.
  • State Street first reported a position in TScan Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • State Street's TScan Therapeutics position peaked at $3.77M in Q3 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.